A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

A Phase III  multi-center  double-blind  randomized withdrawal study of LCI699 following a 24 week  single-arm  open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

Brief description of study

The study aims to confirm the long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease who have had had surgery that has not been successful, or are not a good surgical candidate, or refuse surgery, and have not received radiation treatment for this condition within the past three years. . LC1699 is taken in pill form twice a day. Once eligibility has been confirmed, the study has four periods plus an optional extension period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cushing syndrome
  • Age: Between 1 Years - 99 Years
  • Gender: All


Updated on 21 Jun 2021. Study ID: 820801

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center